vs
Side-by-side financial comparison of Becton Dickinson (BDX) and LPL Financial Holdings Inc. (LPLA). Click either name above to swap in a different company.
Becton Dickinson is the larger business by last-quarter revenue ($5.3B vs $4.9B, roughly 1.1× LPL Financial Holdings Inc.). Becton Dickinson runs the higher net margin — 7.3% vs 6.1%, a 1.2% gap on every dollar of revenue. On growth, LPL Financial Holdings Inc. posted the faster year-over-year revenue change (40.4% vs -0.4%). LPL Financial Holdings Inc. produced more free cash flow last quarter ($613.3M vs $549.0M). Over the past eight quarters, LPL Financial Holdings Inc.'s revenue compounded faster (32.0% CAGR vs 2.0%).
Becton, Dickinson and Company is an American multinational medical technology company that manufactures and sells medical devices, instrument systems, and reagents. BD also provides consulting and analytics services in certain areas.
LPL Financial Holdings Inc. was founded in 1989 and is considered the largest independent broker-dealer in the United States. As of 2021 the company had more than 17,500 financial advisors, over US$1 trillion in advisory and brokerage assets, and generated approximately $10.3 billion in annual revenue for the 2023 fiscal year. LPL Financial has main offices in Boston, Fort Mill, Austin, and San Diego. The company is a member of FINRA and the SIPC.
BDX vs LPLA — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $5.3B | $4.9B |
| Net Profit | $382.0M | $300.7M |
| Gross Margin | 45.9% | — |
| Operating Margin | 10.5% | 8.1% |
| Net Margin | 7.3% | 6.1% |
| Revenue YoY | -0.4% | 40.4% |
| Net Profit YoY | 24.0% | 11.1% |
| EPS (diluted) | $1.34 | $3.65 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $5.3B | $4.9B | ||
| Q3 25 | $5.9B | $4.6B | ||
| Q2 25 | $5.5B | $3.8B | ||
| Q1 25 | $5.3B | $3.7B | ||
| Q4 24 | $5.2B | $3.5B | ||
| Q3 24 | $5.4B | $3.1B | ||
| Q2 24 | $5.0B | $2.9B | ||
| Q1 24 | $5.0B | $2.8B |
| Q4 25 | $382.0M | $300.7M | ||
| Q3 25 | $493.0M | $-29.5M | ||
| Q2 25 | $574.0M | $273.2M | ||
| Q1 25 | $308.0M | $318.6M | ||
| Q4 24 | $303.0M | $270.7M | ||
| Q3 24 | $400.0M | $255.3M | ||
| Q2 24 | $487.0M | $243.8M | ||
| Q1 24 | $537.0M | $288.8M |
| Q4 25 | 45.9% | — | ||
| Q3 25 | 47.5% | — | ||
| Q2 25 | 47.8% | — | ||
| Q1 25 | 42.8% | — | ||
| Q4 24 | 43.2% | — | ||
| Q3 24 | 45.7% | — | ||
| Q2 24 | 46.2% | — | ||
| Q1 24 | 45.7% | — |
| Q4 25 | 10.5% | 8.1% | ||
| Q3 25 | 11.8% | -0.7% | ||
| Q2 25 | 16.0% | 9.6% | ||
| Q1 25 | 10.4% | 11.4% | ||
| Q4 24 | 8.8% | 9.7% | ||
| Q3 24 | 11.4% | 11.2% | ||
| Q2 24 | 12.1% | 11.3% | ||
| Q1 24 | 14.5% | 13.2% |
| Q4 25 | 7.3% | 6.1% | ||
| Q3 25 | 8.4% | -0.6% | ||
| Q2 25 | 10.4% | 7.1% | ||
| Q1 25 | 5.8% | 8.7% | ||
| Q4 24 | 5.9% | 7.7% | ||
| Q3 24 | 7.4% | 8.2% | ||
| Q2 24 | 9.8% | 8.3% | ||
| Q1 24 | 10.6% | 10.2% |
| Q4 25 | $1.34 | $3.65 | ||
| Q3 25 | $1.71 | $-0.37 | ||
| Q2 25 | $2.00 | $3.40 | ||
| Q1 25 | $1.07 | $4.24 | ||
| Q4 24 | $1.04 | $3.58 | ||
| Q3 24 | $1.37 | $3.39 | ||
| Q2 24 | $1.68 | $3.23 | ||
| Q1 24 | $1.85 | $3.83 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $740.0M | $1.1B |
| Total DebtLower is stronger | — | $7.3B |
| Stockholders' EquityBook value | $25.3B | $5.3B |
| Total Assets | $54.8B | $18.5B |
| Debt / EquityLower = less leverage | — | 1.36× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $740.0M | $1.1B | ||
| Q3 25 | $641.0M | $1.6B | ||
| Q2 25 | $735.0M | $4.3B | ||
| Q1 25 | $667.0M | $1.4B | ||
| Q4 24 | $711.0M | $1.0B | ||
| Q3 24 | $1.7B | $1.6B | ||
| Q2 24 | $4.5B | $1.4B | ||
| Q1 24 | $2.3B | $1.2B |
| Q4 25 | — | $7.3B | ||
| Q3 25 | — | $7.5B | ||
| Q2 25 | — | $7.2B | ||
| Q1 25 | — | $5.7B | ||
| Q4 24 | — | $5.5B | ||
| Q3 24 | — | $4.4B | ||
| Q2 24 | — | $4.4B | ||
| Q1 24 | — | $3.9B |
| Q4 25 | $25.3B | $5.3B | ||
| Q3 25 | $25.4B | $5.0B | ||
| Q2 25 | $25.5B | $5.1B | ||
| Q1 25 | $25.2B | $3.1B | ||
| Q4 24 | $25.2B | $2.9B | ||
| Q3 24 | $25.9B | $2.8B | ||
| Q2 24 | $25.9B | $2.5B | ||
| Q1 24 | $25.6B | $2.3B |
| Q4 25 | $54.8B | $18.5B | ||
| Q3 25 | $55.3B | $18.0B | ||
| Q2 25 | $54.9B | $17.5B | ||
| Q1 25 | $54.5B | $14.0B | ||
| Q4 24 | $54.7B | $13.3B | ||
| Q3 24 | $57.3B | $11.9B | ||
| Q2 24 | $55.6B | $11.5B | ||
| Q1 24 | $54.2B | $11.0B |
| Q4 25 | — | 1.36× | ||
| Q3 25 | — | 1.49× | ||
| Q2 25 | — | 1.41× | ||
| Q1 25 | — | 1.82× | ||
| Q4 24 | — | 1.87× | ||
| Q3 24 | — | 1.60× | ||
| Q2 24 | — | 1.77× | ||
| Q1 24 | — | 1.70× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $657.0M | $785.0M |
| Free Cash FlowOCF − Capex | $549.0M | $613.3M |
| FCF MarginFCF / Revenue | 10.5% | 12.4% |
| Capex IntensityCapex / Revenue | 2.1% | 3.5% |
| Cash ConversionOCF / Net Profit | 1.72× | 2.61× |
| TTM Free Cash FlowTrailing 4 quarters | $2.6B | $-981.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $657.0M | $785.0M | ||
| Q3 25 | $1.4B | $-1.7B | ||
| Q2 25 | $1.2B | $193.3M | ||
| Q1 25 | $164.0M | $339.8M | ||
| Q4 24 | $693.0M | $-178.8M | ||
| Q3 24 | $1.2B | $209.3M | ||
| Q2 24 | $1.3B | $-178.9M | ||
| Q1 24 | $514.0M | $425.9M |
| Q4 25 | $549.0M | $613.3M | ||
| Q3 25 | $1.0B | $-1.9B | ||
| Q2 25 | $1.0B | $56.3M | ||
| Q1 25 | $35.0M | $220.3M | ||
| Q4 24 | $588.0M | $-344.3M | ||
| Q3 24 | $882.0M | $62.3M | ||
| Q2 24 | $1.1B | $-307.8M | ||
| Q1 24 | $380.0M | $304.9M |
| Q4 25 | 10.5% | 12.4% | ||
| Q3 25 | 17.0% | -41.1% | ||
| Q2 25 | 19.0% | 1.5% | ||
| Q1 25 | 0.7% | 6.0% | ||
| Q4 24 | 11.4% | -9.8% | ||
| Q3 24 | 16.2% | 2.0% | ||
| Q2 24 | 22.4% | -10.5% | ||
| Q1 24 | 7.5% | 10.8% |
| Q4 25 | 2.1% | 3.5% | ||
| Q3 25 | 6.0% | 3.1% | ||
| Q2 25 | 3.2% | 3.6% | ||
| Q1 25 | 2.4% | 3.3% | ||
| Q4 24 | 2.0% | 4.7% | ||
| Q3 24 | 5.4% | 4.7% | ||
| Q2 24 | 3.6% | 4.4% | ||
| Q1 24 | 2.7% | 4.3% |
| Q4 25 | 1.72× | 2.61× | ||
| Q3 25 | 2.75× | — | ||
| Q2 25 | 2.12× | 0.71× | ||
| Q1 25 | 0.53× | 1.07× | ||
| Q4 24 | 2.29× | -0.66× | ||
| Q3 24 | 2.94× | 0.82× | ||
| Q2 24 | 2.66× | -0.73× | ||
| Q1 24 | 0.96× | 1.47× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BDX
| Other | $2.8B | 53% |
| Medication Management Solutions | $678.0M | 13% |
| Urologyand Critical Care | $339.0M | 6% |
| Surgery | $310.0M | 6% |
| Peripheral Intervention | $265.0M | 5% |
| Specimen Management | $245.0M | 5% |
| Advanced Patient Monitoring | $178.0M | 3% |
| Diagnostic Solutions | $176.0M | 3% |
| Bio Pharma Systems | $150.0M | 3% |
| Biosciences | $124.0M | 2% |
LPLA
Segment breakdown not available.
